|
US4271068A
(en)
|
1968-05-10 |
1981-06-02 |
Ciba-Geigy Corporation |
Process for the manufacture of cystine-containing peptides
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4033940A
(en)
|
1975-11-12 |
1977-07-05 |
Armour Pharmaceutical Company |
Cyclization of peptides
|
|
US4216141A
(en)
|
1978-07-19 |
1980-08-05 |
The Salk Institute For Biological Studies |
Method for cyclization of peptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
NZ199722A
(en)
|
1981-02-25 |
1985-12-13 |
Genentech Inc |
Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5371109A
(en)
|
1986-07-01 |
1994-12-06 |
Drilletten Ab |
Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
ES2118066T3
(es)
|
1989-10-05 |
1998-09-16 |
Optein Inc |
Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
|
|
US5585353A
(en)
|
1990-02-02 |
1996-12-17 |
The Rockefeller University |
Antibiotic peptides containing D-amino acids
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5766897A
(en)
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
|
US5843701A
(en)
|
1990-08-02 |
1998-12-01 |
Nexstar Pharmaceticals, Inc. |
Systematic polypeptide evolution by reverse translation
|
|
US5270170A
(en)
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
CA2163620A1
(en)
|
1993-05-28 |
1994-12-08 |
Michael V. Doyle |
Method for selection of biologically active peptide sequences
|
|
WO1995001368A1
(en)
|
1993-06-29 |
1995-01-12 |
Ferring B.V. |
Improved synthesis of cyclic peptides
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
US5834318A
(en)
|
1995-05-10 |
1998-11-10 |
Bayer Corporation |
Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
|
|
US5912014A
(en)
|
1996-03-15 |
1999-06-15 |
Unigene Laboratories, Inc. |
Oral salmon calcitonin pharmaceutical products
|
|
US6720472B2
(en)
|
1996-07-12 |
2004-04-13 |
University Of Medicine And Dentistry Of New Jersey |
HMGI proteins in cancer and obesity
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
EP0962527B1
(en)
|
1996-10-17 |
2004-08-04 |
Mitsubishi Chemical Corporation |
Molecule that homologizes genotype and phenotype and utilization thereof
|
|
US6348584B1
(en)
|
1996-10-17 |
2002-02-19 |
John Edward Hodgson |
Fibronectin binding protein compounds
|
|
US5922680A
(en)
|
1996-10-23 |
1999-07-13 |
Ferring, B.V. |
Stabilized composition for oral administration of peptides
|
|
US6261804B1
(en)
|
1997-01-21 |
2001-07-17 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
|
DK0971946T3
(da)
|
1997-01-21 |
2006-10-30 |
Gen Hospital Corp |
Selektion af proteiner ved anvendelse af RNA-protein-fusioner
|
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
|
JP3614866B2
(ja)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ，インコーポレイティド |
人工抗体ポリペプチド
|
|
EP0896001A1
(en)
|
1997-08-08 |
1999-02-10 |
Daicel Chemical Industries, Ltd. |
Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
|
|
US6429301B1
(en)
|
1998-04-17 |
2002-08-06 |
Whitehead Institute For Biomedical Research |
Use of a ribozyme to join nucleic acids and peptides
|
|
IL140930A0
(en)
|
1998-08-07 |
2002-02-10 |
Emisphere Tech Inc |
Compounds and compositions for delivering active agents
|
|
WO2000021559A2
(en)
|
1998-10-09 |
2000-04-20 |
Musc Foundation For Research Development |
Blocking factor b to treat complement-mediated immune disease
|
|
US6962781B1
(en)
|
2000-05-19 |
2005-11-08 |
Proteonova, Inc. |
In vitro evolution of nucleic acids and encoded polypeptide
|
|
US7244701B2
(en)
|
2000-06-16 |
2007-07-17 |
Zealand Phama A/S |
Diuretic peptide conjugate
|
|
WO2004103294A2
(en)
|
2003-05-15 |
2004-12-02 |
Tanox, Inc. |
Methods and compositions for the prevention and treatment of sepsis
|
|
US7348401B2
(en)
|
2003-09-10 |
2008-03-25 |
Innate Biotech, Inc. |
Peptides that inhibit complement activation
|
|
US20050191343A1
(en)
|
2003-11-26 |
2005-09-01 |
Shire Laboratories, Inc. |
Micellar systems useful for delivery of lipophilic or hydrophobic compounds
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
WO2006066258A2
(en)
|
2004-12-17 |
2006-06-22 |
Neose Technologies, Inc. |
Lipoconjugation of peptides
|
|
PT1844337E
(pt)
|
2005-01-24 |
2014-04-03 |
Pepscan Systems Bv |
Compostos ligantes, compostos imunogénicos e peptidomiméticos
|
|
EP1874289A2
(en)
|
2005-03-29 |
2008-01-09 |
Cardax Pharmaceuticals, Inc. |
Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
|
|
US8911733B2
(en)
|
2005-05-26 |
2014-12-16 |
Musc Foundation For Research Development |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
|
CN101217940B
(zh)
|
2005-06-06 |
2013-03-27 |
卡穆鲁斯公司 |
Glp-1类似物制剂
|
|
PT2500030E
(pt)
|
2005-11-04 |
2015-09-24 |
Genentech Inc |
Uso de inibidores da via do complemento para tratar doenças oculares
|
|
ES2965283T3
(es)
*
|
2006-03-15 |
2024-05-28 |
Alexion Pharma Inc |
Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
|
|
EP1876183A1
(en)
|
2006-07-04 |
2008-01-09 |
Technische Universität München |
Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
|
|
SI3028716T1
(sl)
|
2006-10-10 |
2021-01-29 |
Regenesance B.V. |
Komplementarna inhibicija za izboljšano regeneracijo živcev
|
|
US7736860B2
(en)
|
2006-11-09 |
2010-06-15 |
Univeristy Of Massachusetts |
Methods of identifying compounds for the treatment of sterile inflammation
|
|
MX2009010181A
(es)
|
2007-03-22 |
2009-12-04 |
Novartis Ag |
Antigenos c5 y usos de los mismos.
|
|
US20100015139A1
(en)
|
2008-07-10 |
2010-01-21 |
Rekha Bansal |
METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
|
|
RU2009144142A
(ru)
|
2007-04-30 |
2011-06-10 |
Алькон Рисерч, Лтд. (Us) |
Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента
|
|
KR101572700B1
(ko)
|
2007-06-07 |
2015-11-30 |
제넨테크, 인크. |
보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
|
|
WO2009014633A1
(en)
|
2007-07-20 |
2009-01-29 |
Trustees Of The University Of Pennsylvania |
Method of treating acute respiratory distress syndrome
|
|
WO2009046198A2
(en)
*
|
2007-10-02 |
2009-04-09 |
Potentia Pharmaceuticals, Inc. |
Sustained delivery of compstatin analogs from gels
|
|
WO2009067191A2
(en)
|
2007-11-16 |
2009-05-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of hepatitis c virus (hcv) infection
|
|
WO2009121065A2
(en)
|
2008-03-28 |
2009-10-01 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
WO2010014830A2
(en)
|
2008-07-30 |
2010-02-04 |
Cosmix Therapeutics Llc |
Peptide therapeutics that bind vegf and methods of use thereof
|
|
WO2010025510A1
(en)
|
2008-09-03 |
2010-03-11 |
Xenome Ltd |
Libraries of peptide conjugates and methods for making them
|
|
US9447176B2
(en)
|
2008-11-10 |
2016-09-20 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
AU2009230735B1
(en)
|
2009-01-08 |
2010-01-21 |
Shane Ramodien |
Electronic equipment housing
|
|
AU2010306581B2
(en)
|
2009-10-16 |
2015-03-19 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
|
|
EP2496259B1
(en)
|
2009-11-05 |
2017-02-22 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria
|
|
CA2784757A1
(en)
|
2009-12-16 |
2011-07-07 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
US9358266B2
(en)
|
2010-02-25 |
2016-06-07 |
The Trustees Of The University Of Pennsylvania |
Treatment of sepsis using complement inhibitors
|
|
WO2011137363A1
(en)
|
2010-04-30 |
2011-11-03 |
Allergan, Inc. |
Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
|
|
TW201241008A
(en)
*
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
CA2831563A1
(en)
*
|
2011-03-29 |
2012-10-04 |
Abbvie Inc. |
Improved shroud deployment in automatic injection devices
|
|
CN107638565B
(zh)
|
2011-04-08 |
2021-12-21 |
莱斯特大学 |
用于治疗与masp-2依赖性补体活化相关的状况的方法
|
|
AU2012250614B2
(en)
*
|
2011-05-05 |
2016-02-11 |
Pharma Cinq, Llc |
Complement factor B analogs and their uses
|
|
WO2012162215A1
(en)
|
2011-05-20 |
2012-11-29 |
The Trustees Of The University Of Pennsylvania |
Promotion of fracture healing using complement inhibitors
|
|
WO2012174055A1
(en)
|
2011-06-13 |
2012-12-20 |
The Trustees Of The University Of Pennsylvania |
Wound healing using complement inhibitors
|
|
CN102321170B
(zh)
|
2011-09-14 |
2013-11-13 |
深圳翰宇药业股份有限公司 |
利拉鲁肽变构体及其缀合物
|
|
WO2013052736A2
(en)
|
2011-10-06 |
2013-04-11 |
The Medicines Company |
Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
|
|
RS58503B1
(sr)
|
2012-02-20 |
2019-04-30 |
Swedish Orphan Biovitrum Ab Publ |
Polipeptidi koji se vezuju za humani komplement c5
|
|
US20130246083A1
(en)
|
2012-03-16 |
2013-09-19 |
Alexion Pharmaceuticals, Inc. |
Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
|
|
EP2850095B1
(en)
|
2012-05-17 |
2019-10-09 |
RA Pharmaceuticals, Inc. |
Peptide and peptidomimetic inhibitors
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
WO2014078622A1
(en)
|
2012-11-15 |
2014-05-22 |
The Brigham And Women's Hospital, Inc. |
Method and system for diagnosing and treating preeclampsia
|
|
US9700633B2
(en)
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
|
US20140234275A1
(en)
|
2013-02-15 |
2014-08-21 |
Jason Williams |
Method for treating als via the increased production of factor h
|
|
WO2015025312A1
(en)
|
2013-08-21 |
2015-02-26 |
Cannabics Pharmaceuticals Inc |
Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
|
|
CN104231085B
(zh)
*
|
2013-09-05 |
2017-03-15 |
复旦大学附属肿瘤医院 |
靶向特异性补体系统抑制剂、其制备方法及应用
|
|
JP6718379B2
(ja)
|
2014-03-20 |
2020-07-08 |
インフラルクス ゲーエムベーハー |
ウイルス性肺炎治療のためのＣ５ａの阻害剤
|
|
HUE045646T2
(hu)
|
2014-06-12 |
2020-01-28 |
Ra Pharmaceuticals Inc |
Komplement aktivitás modulálása
|
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
CN107427482A
(zh)
|
2015-01-21 |
2017-12-01 |
帕西拉制药有限公司 |
凝血酸的多囊脂质体制剂
|
|
WO2016123371A1
(en)
*
|
2015-01-28 |
2016-08-04 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
EP4218790B1
(en)
*
|
2015-12-16 |
2026-02-18 |
UCB Holdings, Inc. |
Modulators of complement activity
|
|
CA3045114A1
(en)
|
2016-12-07 |
2018-06-14 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
EP3978523A1
(en)
|
2017-04-03 |
2022-04-06 |
InflaRx GmbH |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
|
EP3682016A4
(en)
|
2017-09-11 |
2021-06-02 |
RA Pharmaceuticals, Inc. |
FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
|
|
KR20200095485A
(ko)
|
2017-12-04 |
2020-08-10 |
라 파마슈티컬스 인코포레이티드 |
보체 활성의 조절인자
|
|
EP3934675A2
(en)
|
2019-03-08 |
2022-01-12 |
RA Pharmaceuticals, Inc. |
Zilucoplan as deep tissue penetrating c5 inhibitor
|
|
CA3137895A1
(en)
|
2019-04-24 |
2020-10-29 |
Ra Pharmaceuticals, Inc. |
Compositions and methods for modulating complement activity
|